Reduced T-cell repertoire restrictions in abatacept-treated rheumatoid arthritis patients

Table 2 Variations of T-cell subpopulations after therapy with ABA and comparison with healthy controls

	HC ^a	p	RA T0 ^b	RA T12 ^c	p
		(HC vs. T0)			(RA T0 vs. RA T12)
CD4⁺CD28^neg (%)	3.6 (2.6-4.5)	0.996	5.0 (2.5-8.7)	1.6 (0.4-9.2)	0.032
CD4⁺CD28^neg (cells/μL)	34 (22-78)	0.588	35 (21-76)	15 (8-25)	0.096
CD8 + CD28^neg (%)	14.6 (7.3-23.1)	<0.001	39.4 (25.6-50.4)	27.8 (14.8-35.6)	0.012
CD8⁺CD28^neg (cells/μL)	53 (28-117)	0.072	96 (58-148)	44 (30-95)	0.006
CD4⁺CD45RA⁺CD31⁺ RTE^d (%)	25.0 (20.6-25.8)	1.000	18.4 (14-29.2)	19.3 (15.7-32.1)	1.000
CD4⁺CD45RA⁺CD31⁺ RTE (cells/μL)	182 (138-202)	0.582	155 (98-307)	226 (123-344)	1.000
CD4⁺CD45RA⁺CCR7⁻ (%)	0.9 (0.4-1.6)	0.164	2.1 (0.5-5.1)	0.9 (0.6-1.9)	0.076
CD4⁺CD45RA⁺CCR7⁻ (cells/μL)	6 (5-11)	0.340	13 (6-27)	9 (3-28)	0.132

Data are expressed as median and IQR.
^aHC: healthy controls; ^bT0: before ABA therapy; ^cT12: after 12 months of ABA therapy; ^dRTE: recent T emigrants.

ISSN: 1479-5876